How Much Change Is Enough to Be Compliant with ICH E6(R3)?
Discover how proportionality of risk prioritises what truly matters to protect patients and ensure data integrity.
Proportionality of Risk in Clinical Trials
Discover how proportionality of risk prioritises what truly matters to protect patients and ensure data integrity.
The Biggest Change in Clinical Trials Starts with Sponsors
As sponsors adapt to ICH R3, we explore whether sites are getting the support they need to keep up.
Quality by Design Is the Industry’s Best Bet for Clinical Trials
QbD is the most effective way to protect participants and data in clinical trials, yet the industry still struggles to make it a priority.
Why You Need to Be Clued Up on GCP
TRI’s GCP e-learning module turns ICH E6(R3) principles into practical, scenario-based training.
Risk-Based Approaches
Risk-based approaches are everyone’s top priority in clinical trials, but no one seems to have a clear playbook.
TRI at Scope Europe 2025
TRI CEO Duncan Hall will be at Scope Europe 2025, sharing how technology is meeting the evolving needs of RBQM.
Is ICH E6(R3) Stalling?
Despite high awareness, ICH E6(R3) adoption is stalling, only 19% of organizations report significant change.
Why Early Alignment on Risk Tolerance Is Critical for Clinical Trials
Early alignment on risk tolerance is essential to ensure efficient, compliant trial execution.
TRI Fest: Where Remote Becomes Remarkable
TRI Fest 2025 brought our team together for a day of collaboration and a bit of friendly chaos.